Mission & Story
Mission
At A2A Pharmaceuticals, our mission is to leverage proprietary computational systems, including A.I., to accelerate development of novel drug alternatives for life threatening diseases like cancer, bacterial infections and muscular dystrophy.
Founding Story
Founded by Edward Painter (MBA, Chairman & CIO) with seed funding through SOSV and incubation at IndieBio in 2017. Painter has 30 years of finance experience with Goldman Sachs, Credit Suisse, UBS, and other major financial institutions.
Clinical Focus
Medical conditions and clinical areas addressed by A2A Pharmaceuticals.
Who It Serves
Milestones & Awards
Recent Milestones
Phase 1 clinical trial progress announced May 2025 with tumor reductions in women's cancers. FDA IND clearance for TACC3 program in 2021. Biomea Fusion JV formation for MLL-Menin program. Dose expansion planned for summer 2025 to include additional cancer types.
Awards & Recognition
Winner of Johnson & Johnson Innovation and Janssen Research & Development's Artificial Intelligence for Drug Discovery Quickfire Challenge
Key Partnerships
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Adaptyv Bio
11-50 employees
Adaptyv Bio operates the world's fastest protein validation lab, providing automated experimental testing services for AI-designed proteins. The company enables protein engineers to validate binding, expression, and thermostability of novel protein designs through a fully automated platform with 3-week turnaround times.
Aitia
Aitia is a drug discovery and development company leveraging AI and computational biology to identify novel therapeutic targets and accelerate drug development.
Anagenex
Anagenex is a biotechnology company focused on drug discovery and development. The company appears to operate in the pharmaceutical research space, though specific details about their technology platform, therapeutic areas, and target markets are not available from the provided content.
Aqemia
Aqemia is a drug discovery company advancing next-generation medicines using generative AI and deep physics. The company combines AI-augmented discovery with computational chemistry to develop novel therapeutics at scale.
Arctoris
51-200 employees
Arctoris is a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies through its Ulysses® robotic platform.
Aria Pharmaceuticals
Aria Pharmaceuticals appears to be a pharmaceutical company focused on drug discovery and development. Based on the limited information available, the company operates in the pharmaceutical sector.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.